Capricor Therapeutics Fined for Securities Fraud, Lawsuit Filed

Generated byAinvest NewsReviewed byDavid Feng

Monday, Sep 14, 2026 6:23 am ET1min read

Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Capricor TherapeuticsCAPR-- (NASDAQ:CAPR) and its senior executives for securities fraud following a significant stock drop. Investors have until September 28, 2026, to request appointment as lead plaintiff. The complaint alleges securities fraud under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit is pending in the U.S. District Court for the Southern District of California.

Ainvest News

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue